A randomized study found that a weight‑maintaining ketogenic diet improved a marker of beta cell stress in people with Type 2 diabetes, but experts warn results are preliminary
Researchers publishing on 21 April 2026 reported that adults with Type 2 diabetes placed on a high‑fat, very low‑carbohydrate plan showed measurable improvement in a blood marker tied to pancreatic workload. The trial, led by scientists at the University of Alabama at Birmingham and released in the Journal of the Endocrine Society, compared a ketogenic approach with a conventional low‑fat diet over a short period.
The study drew attention because diets were prescribed to be weight‑maintaining, meaning observed changes were not driven by major weight loss alone. The published findings and discussion were updated on 21 April 2026 to reflect additional context and commentary.
The eating pattern under study is the ketogenic diet, a regimen high in fat, moderate in protein and very low in carbohydrates designed to induce ketosis, a metabolic state in which the body shifts to burning fat for fuel. In clinical and lay conversations ketosis is often framed as a mechanism that alters glucose handling and insulin demand.
In this trial the investigators sought to understand whether that metabolic shift could directly affect pancreatic function, rather than only influence body weight or blood sugar levels.
How the study was structured and what it found
The trial enrolled 51 adults with Type 2 diabetes, most aged between 55 and 62, and assigned them to either a ketogenic or a low‑fat diet that maintained body weight. After three months the team measured changes in the proinsulin‑to‑C‑peptide ratio, a laboratory indicator of how strained insulin‑producing cells are. While both groups lost a modest amount of weight, participants on the ketogenic diet showed a larger reduction in the proportion of proinsulin secreted relative to C‑peptide. Lead author Marian Yurchishin reported these findings as evidence that the ketogenic pattern can improve aspects of beta cell function beyond effects produced solely by calorie loss.
Interpreting the biomarker and clinical meaning
The proinsulin‑to‑C‑peptide ratio serves as a surrogate for pancreatic strain: higher values typically indicate that beta cells are releasing a greater share of immature insulin precursors, a sign of dysfunction. A decline in this ratio suggests reduced stress on those cells and potentially improved capacity to secrete mature insulin when needed. Although the change observed in the ketogenic arm points to a favorable biological effect on beta cells, investigators caution that a biomarker shift does not equate to durable disease reversal. The authors emphasize that beyond interventions like bariatric surgery or major weight reduction, few strategies have demonstrated direct improvement in beta‑cell performance.
Benefits, limitations, and the need for longer studies
This research raises the possibility that a targeted macronutrient change can alter pancreatic workload independently of large weight loss, offering a complementary tool for metabolic management. However, the study is small and short term, so generalizing the results would be premature. The investigators and outside endocrinologists note that confirming long‑term benefits for blood glucose control, complication risk and sustained beta‑cell health requires larger, longer trials. Personalized response is likely: what benefits one individual’s metabolic profile may not suit another, particularly given differing cardiovascular risk factors and medication regimens.
Concerns from other research
Separate work from the University of Bath raised potential drawbacks of very low‑carbohydrate ketogenic plans. In that trial, participants on a ketogenic regimen for 12 weeks displayed rises in blood cholesterol and reductions in certain beneficial members of the gut microbiome. Changes in gut bacterial composition can influence digestion, immunity and metabolic health, and some cholesterol changes may raise cardiovascular concerns. Researchers stressed that responses varied among participants and that longer follow‑up is necessary to determine net clinical impact.
Practical takeaways for patients and clinicians
For people with Type 2 diabetes, the new study suggests the ketogenic diet could reduce pancreatic strain as indicated by biomarker changes, but it is not definitive evidence of disease reversal. Clinicians should weigh potential metabolic benefits against possible effects on cholesterol and the gut microbiome, and decisions should consider individual risk profiles and treatment goals. The authors call for larger randomized trials that track clinical outcomes and safety over time. Until then, any adoption of a ketogenic plan should be supervised by healthcare professionals and integrated into a broader care strategy that monitors both glycemic control and cardiovascular health.
